Successful use of a janus kinase inhibitor for the treatment of atopic dermatitis

Abstract

The article presents a clinical report of the use of a new drug of the janus kinase inhibitor, upadacitinib, possessing of the effect on the intracellular JAK/STAT system, the role of which in the pathogenesis of atopic dermatitis (AD) is being actively studied. JAK/STAT includes janus kinases JAK1, JAK2, JAK3, tyrosine kinase, protein-transductor and transcription activator (STAT). When the cytokine interacts with the corresponding receptor, janus kinases phosphorylate STAT proteins inducing transcription of genes that mediate the action of key cytokines to trigger the development of an inflammatory response in the shock organ. Upadacitinib is recommended for uncontrolled AD patients older 12 years. The use of upadacitinib in a 17-year-old patient at a dose of 15 mg in tablets, daily, has shown high efficacy in achieving clinical remission of AD and complete relief of the skin itching.